The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

Nektar Therapeutics Surges 16.5% on Positive Clinical Data and Analyst Upgrades

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Nektar Therapeutics (NKTR) shares jumped 16.5% following the release of positive efficacy and safety data for its atopic dermatitis treatment, Rezpeg. The clinical success prompted a wave of bullish sentiment from institutional analysts, providing a significant boost to the stock's performance. Major firms including BTIG, H.C. Wainwright, and William Blair responded by raising their ratings and price targets for the biotech company. In a strategic move to capitalize on this momentum, Nektar announced plans for a $300 million public offering to fund further research and development. While the capital raise may introduce some dilutionary pressure, the market's focus remains firmly on the therapeutic potential of the company's pipeline. This surge highlights the high sensitivity of biotech stocks to clinical trial milestones and subsequent institutional validation.